Cabaletta Bio Unveils New Clinical Data for Rese-cel in Autoimmune Diseases
Written by Emily J. Thompson, Senior Investment Analyst
Updated: Jun 03 2026
0mins
Source: Newsfilter
- Clinical Trial Success: In the Phase 1/2 RESET-Myositis study, 83% of dermatomyositis patients met the registrational primary endpoint, with all patients maintaining their responses off immunomodulators during the latest follow-up, indicating the long-term efficacy of rese-cel and potentially laying the groundwork for future registration applications.
- Juvenile Patient Response: The first juvenile dermatomyositis patient demonstrated a moderate TIS response off immunomodulators, maintaining this response through the latest follow-up at 32 weeks, with expectations to include this in the 2H27 myositis BLA submission, potentially securing a priority review voucher.
- New Indication for Systemic Sclerosis: Systemic sclerosis has been announced as a second pivotal indication based on Phase 1/2 data, with a single-arm registrational study anticipated to initiate in 4Q26 involving approximately 25 patients, further validating the clinical application potential of rese-cel.
- Immune System Reset: The lowest dose of PC-free rese-cel achieved deep B cell depletion in one of the first two lupus patients treated, demonstrating that for most patients, a single dose of rese-cel can provide significant immune system reset effects that persist over time, potentially altering treatment strategies.
Trade with 70% Backtested Accuracy
Stop guessing "Should I Buy CABA?" and start using high-conviction signals backed by rigorous historical data.
Sign up today to access powerful investing tools and make smarter, data-driven decisions.
Analyst Views on CABA
Wall Street analysts forecast CABA stock price to rise
6 Analyst Rating
5 Buy
1 Hold
0 Sell
Strong Buy
Current: 2.840
Low
4.00
Averages
12.60
High
16.00
Current: 2.840
Low
4.00
Averages
12.60
High
16.00
About CABA
Cabaletta Bio, Inc. is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies that have the potential to provide deep and durable, perhaps curative, responses with one-time administration for patients with autoimmune diseases. Its Cabaletta Approach to B cell Ablation (CABA) platform encompasses two strategies: Chimeric Antigen Receptor T cells for Autoimmunity (CARTA) and Chimeric AutoAntibody Receptor T cells (CAART). Resecabtagene autoleucel, its lead product candidate from its CARTA platform, is a 4-1BB co-stimulatory domain-containing fully human CD19-CAR T construct designed to treat patients with a range of autoimmune diseases. Its DSG3-CAART product candidate is being evaluated for the treatment of mPV, a subtype of PV that affects the epithelium of the mucous membranes, in the Phase 1 DesCAARTes TM trial. Its MuSK-CAART product candidate is designed to treat a subset of patients with MG, targeting autoreactive B cells.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
Cabaletta Bio Unveils New Clinical Data for Rese-cel in Autoimmune Diseases
- Clinical Trial Success: In the Phase 1/2 RESET-Myositis study, 83% of dermatomyositis patients met the registrational primary endpoint, with all patients maintaining their responses off immunomodulators during the latest follow-up, indicating the long-term efficacy of rese-cel and potentially laying the groundwork for future registration applications.
- Juvenile Patient Response: The first juvenile dermatomyositis patient demonstrated a moderate TIS response off immunomodulators, maintaining this response through the latest follow-up at 32 weeks, with expectations to include this in the 2H27 myositis BLA submission, potentially securing a priority review voucher.
- New Indication for Systemic Sclerosis: Systemic sclerosis has been announced as a second pivotal indication based on Phase 1/2 data, with a single-arm registrational study anticipated to initiate in 4Q26 involving approximately 25 patients, further validating the clinical application potential of rese-cel.
- Immune System Reset: The lowest dose of PC-free rese-cel achieved deep B cell depletion in one of the first two lupus patients treated, demonstrating that for most patients, a single dose of rese-cel can provide significant immune system reset effects that persist over time, potentially altering treatment strategies.
See More
Cabaletta Bio Reports Q1 Earnings Beat
- Earnings Beat: Cabaletta Bio reported a Q1 GAAP EPS of -$0.39, beating expectations by $0.01, indicating a slight improvement in financial performance that may bolster investor confidence.
- Cash Position: As of March 31, 2026, the company had $116.6 million in cash and short-term investments, down from $133.6 million as of December 31, 2025, reflecting pressure on operational funding management and necessitating attention to future financing strategies.
- Funding Outlook: Cabaletta expects its cash position as of March 31, 2026, along with funds raised from the May 2026 registered direct offering, to support its operating plan into mid-2027, demonstrating confidence in future growth and financial stability.
- CAR T Therapy Advancement: The use of Cellares' Cell Shuttle in the first patient infusions of Cabaletta Bio's CAR T therapy marks a significant technological advancement in cell therapy, potentially providing a competitive edge in the market.
See More
Cabaletta Bio's Therapy Shows Promising Results in Pemphigus Vulgaris
- Significant Clinical Activity: Cabaletta Bio's therapy rese-cel, administered without preconditioning to four patients with pemphigus vulgaris, demonstrated compelling clinical activity in two patients over a six-month follow-up, indicating the therapy's potential in treating autoimmune diseases.
- Monitoring Immune Reactions: While a mild immune reaction was noted in one patient, the absence of neurological complications provides initial support for the therapy's safety, potentially enhancing patient confidence in its use.
- Successful Financing Plan: Cabaletta Bio priced an underwritten offering of 51.73 million shares at $2.90 per share, expected to raise approximately $150 million after underwriting discounts and expenses, which will support further research and development efforts.
- Market Sentiment Shift: Retail sentiment around CABA stock shifted from 'neutral' to 'bullish' in the past 24 hours, reflecting optimistic expectations for the company's future, especially following Eli Lilly's participation in the financing, with investors anticipating potential collaboration or acquisition.
See More
Cabaletta Bio Raises $150M Through Share Offering
- Significant Fundraising: Cabaletta Bio priced an underwritten offering of 51.7 million shares at $2.90 each, successfully raising approximately $150 million, demonstrating strong market confidence in its future growth.
- Positive Market Reaction: Following the financing announcement, Cabaletta Bio's shares surged over 16% in premarket trading, reflecting investor optimism regarding the company's prospects.
- Broad Investor Participation: The financing attracted participation from notable investment firms including Bain Capital Life Sciences, Adage Capital Management, and Eli Lilly, indicating strong market recognition and support for its CAR T therapy.
- Transaction Timeline: The sale is expected to close on or about May 5, 2026, subject to customary closing conditions, ensuring timely access to funds to support the company's research and operations.
See More
Cabaletta Bio to Present New Therapy Data at ASGCT Meeting
- Clinical Data Presentation: Cabaletta Bio will showcase clinical and translational data for rese-cel at the 2026 ASGCT Annual Meeting, particularly focusing on its application for autoimmune diseases, which is expected to attract industry attention and enhance the company's reputation in biotechnology.
- Manufacturing Platform Innovation: The company will present initial translational data from the automated Cellares Cell Shuttle™ platform used to manufacture rese-cel, demonstrating its application in autoimmune patients and indicating Cabaletta's technological advancements in cell therapy manufacturing.
- Product Quality Consistency: Data on manufacturing comparability between healthy donors and autoimmune patients will be presented, emphasizing the robustness of the manufacturing process in clinical trials, which may bolster investor confidence in the company's products.
- Diverse Clinical Trials: Cabaletta's RESET™ clinical development program spans multiple autoimmune diseases, showcasing the company's broad application potential in rheumatology, neurology, and dermatology, which could lay the groundwork for future market expansion.
See More
Cellares Successfully Infuses CAR T Therapy into Cabaletta Bio Patients
- Successful Patient Infusion: Cellares announced on Wednesday that Cabaletta Bio's CAR T therapy, rese-cel, has been successfully infused into the first two patients, marking a significant advancement in the clinical trial program.
- Validation of GMP Production: The first two GMP doses of rese-cel were manufactured on the Cell Shuttle automated platform, meeting all release specifications and delivered on time, showcasing Cellares' capabilities in GMP manufacturing and supply chain management.
- Market Opportunity Potential: The Cell Shuttle and Cell Q systems offer highly scalable production capacity that biotech and pharmaceutical companies can secure with minimal capital investment and low cost of goods, presenting significant commercial value.
- Team Collaboration Achievement: Cabaletta Bio CEO Steven Nichtberger stated that this successful infusion reflects focused collaboration between Cellares and Cabaletta teams since 2023, marking a major milestone towards achieving high-capacity flexible supply.
See More
Cabaletta Bio Unveils New Clinical Data for Rese-cel in Autoimmune Diseases
- Clinical Trial Success: In the Phase 1/2 RESET-Myositis study, 83% of dermatomyositis patients met the registrational primary endpoint, with all patients maintaining their responses off immunomodulators during the latest follow-up, indicating the long-term efficacy of rese-cel and potentially laying the groundwork for future registration applications.
- Juvenile Patient Response: The first juvenile dermatomyositis patient demonstrated a moderate TIS response off immunomodulators, maintaining this response through the latest follow-up at 32 weeks, with expectations to include this in the 2H27 myositis BLA submission, potentially securing a priority review voucher.
- New Indication for Systemic Sclerosis: Systemic sclerosis has been announced as a second pivotal indication based on Phase 1/2 data, with a single-arm registrational study anticipated to initiate in 4Q26 involving approximately 25 patients, further validating the clinical application potential of rese-cel.
- Immune System Reset: The lowest dose of PC-free rese-cel achieved deep B cell depletion in one of the first two lupus patients treated, demonstrating that for most patients, a single dose of rese-cel can provide significant immune system reset effects that persist over time, potentially altering treatment strategies.
See More
Cabaletta Bio Reports Q1 Earnings Beat
- Earnings Beat: Cabaletta Bio reported a Q1 GAAP EPS of -$0.39, beating expectations by $0.01, indicating a slight improvement in financial performance that may bolster investor confidence.
- Cash Position: As of March 31, 2026, the company had $116.6 million in cash and short-term investments, down from $133.6 million as of December 31, 2025, reflecting pressure on operational funding management and necessitating attention to future financing strategies.
- Funding Outlook: Cabaletta expects its cash position as of March 31, 2026, along with funds raised from the May 2026 registered direct offering, to support its operating plan into mid-2027, demonstrating confidence in future growth and financial stability.
- CAR T Therapy Advancement: The use of Cellares' Cell Shuttle in the first patient infusions of Cabaletta Bio's CAR T therapy marks a significant technological advancement in cell therapy, potentially providing a competitive edge in the market.
See More
Cabaletta Bio's Therapy Shows Promising Results in Pemphigus Vulgaris
- Significant Clinical Activity: Cabaletta Bio's therapy rese-cel, administered without preconditioning to four patients with pemphigus vulgaris, demonstrated compelling clinical activity in two patients over a six-month follow-up, indicating the therapy's potential in treating autoimmune diseases.
- Monitoring Immune Reactions: While a mild immune reaction was noted in one patient, the absence of neurological complications provides initial support for the therapy's safety, potentially enhancing patient confidence in its use.
- Successful Financing Plan: Cabaletta Bio priced an underwritten offering of 51.73 million shares at $2.90 per share, expected to raise approximately $150 million after underwriting discounts and expenses, which will support further research and development efforts.
- Market Sentiment Shift: Retail sentiment around CABA stock shifted from 'neutral' to 'bullish' in the past 24 hours, reflecting optimistic expectations for the company's future, especially following Eli Lilly's participation in the financing, with investors anticipating potential collaboration or acquisition.
See More
Cabaletta Bio Raises $150M Through Share Offering
- Significant Fundraising: Cabaletta Bio priced an underwritten offering of 51.7 million shares at $2.90 each, successfully raising approximately $150 million, demonstrating strong market confidence in its future growth.
- Positive Market Reaction: Following the financing announcement, Cabaletta Bio's shares surged over 16% in premarket trading, reflecting investor optimism regarding the company's prospects.
- Broad Investor Participation: The financing attracted participation from notable investment firms including Bain Capital Life Sciences, Adage Capital Management, and Eli Lilly, indicating strong market recognition and support for its CAR T therapy.
- Transaction Timeline: The sale is expected to close on or about May 5, 2026, subject to customary closing conditions, ensuring timely access to funds to support the company's research and operations.
See More
Cabaletta Bio to Present New Therapy Data at ASGCT Meeting
- Clinical Data Presentation: Cabaletta Bio will showcase clinical and translational data for rese-cel at the 2026 ASGCT Annual Meeting, particularly focusing on its application for autoimmune diseases, which is expected to attract industry attention and enhance the company's reputation in biotechnology.
- Manufacturing Platform Innovation: The company will present initial translational data from the automated Cellares Cell Shuttle™ platform used to manufacture rese-cel, demonstrating its application in autoimmune patients and indicating Cabaletta's technological advancements in cell therapy manufacturing.
- Product Quality Consistency: Data on manufacturing comparability between healthy donors and autoimmune patients will be presented, emphasizing the robustness of the manufacturing process in clinical trials, which may bolster investor confidence in the company's products.
- Diverse Clinical Trials: Cabaletta's RESET™ clinical development program spans multiple autoimmune diseases, showcasing the company's broad application potential in rheumatology, neurology, and dermatology, which could lay the groundwork for future market expansion.
See More
Cellares Successfully Infuses CAR T Therapy into Cabaletta Bio Patients
- Successful Patient Infusion: Cellares announced on Wednesday that Cabaletta Bio's CAR T therapy, rese-cel, has been successfully infused into the first two patients, marking a significant advancement in the clinical trial program.
- Validation of GMP Production: The first two GMP doses of rese-cel were manufactured on the Cell Shuttle automated platform, meeting all release specifications and delivered on time, showcasing Cellares' capabilities in GMP manufacturing and supply chain management.
- Market Opportunity Potential: The Cell Shuttle and Cell Q systems offer highly scalable production capacity that biotech and pharmaceutical companies can secure with minimal capital investment and low cost of goods, presenting significant commercial value.
- Team Collaboration Achievement: Cabaletta Bio CEO Steven Nichtberger stated that this successful infusion reflects focused collaboration between Cellares and Cabaletta teams since 2023, marking a major milestone towards achieving high-capacity flexible supply.
See More
